Back to results
US 6,605,599 B1Granted
Epothilone derivatives
AssigneeBristol-Myers Squibb Company
InventorsGregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
Life of this patent
Estimating the term…
Abstract
The present invention relates to epothilone derivatives, having the following formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1-R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
Claims62
A compound of the formula:
- wherein:
- Q is selected from the group consisting of:
- G is selected from the group consisting of alkyl;
- substituted alkyl;
- substituted aryl;
- a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- W is O or NR15;
- X is O or H, H;
- Y is selected from the group consisting of O;
- H, OR16;
- OR17, OR17;
- NOR18;
- H,NHOR19;
- H, NR20R21;
- H, H;
- and CHR22;
- wherein OR17, OR17 can be a cyclic ketal;
- Z1 and Z2 are independently CH2;
- B1 and B2 are independently selected from the group consisting of OR24, OCOR25, and O—C(═O)—NR26R27, and when B1 is OH and Y is OH, H, they can form a six-membered ring ketal or acetal;
- R1, R2, R3, R4, R5, R7, R13, R14, R18, R19, R20, R21, R22, R26 and R27 are selected from the group consisting of H, alkyl, substituted alkyl, and aryl, and when R1 and R2 are alkyl can be joined to form a cycloalkyl, and when R3 and R4 are alkyl can be joined to form a cycloalkyl;
- R6is methyl;
- R9, R10, R16, R17, R24, R25 and R31 are selected from the group consisting of H, alkyl, and substituted alkyl;
- R11, R12, R28, R30, R32, and R33 are selected from the group consisting of H;
- alkyl;
- substituted alkyl;
- aryl;
- substituted aryl;
- cycloalkyl containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C3-C7 carbocyclic ring;
- and a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- R8 is hydrogen or methyl;
- R15, R23 and R29 are selected from the group consisting of H;
- alkyl;
- substituted alkyl;
- aryl;
- substituted aryl;
- cycloalkyl containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C3-C7 carbocyclic ring;
- a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- R32C═O;
- R33SO2;
- hydroxy;
- O-alkyl or O-substituted alkyl;
- or pharmaceutically acceptable salts thereof, hydrates, solvates or geometric, optical or stereoisomers thereof;
- with the proviso that compounds wherein
- W and X are both O;
- and
- R1, R2 and R7 are H;
- and
- R3, R4 and R6 are methyl;
- and
- R8 is H or methyl;
- and
- G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl;
- and
- Q is as defined above are excluded.
51 more elements
A compound selected from the group consisting of:
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,13,17-trioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,13,17-trioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1,10-dioxa-13-cyclohexadecene-2,6-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9-tetramethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1,10-dioxa-13-cyclohexadecene-2,6-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,14,17-trioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,14,17-trioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1,11-dioxa-13-cyclohexadecene-2,6-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9-tetramethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1,11-dioxa-13-cyclohexadecene-2,6-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-9-one;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-9-one;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-3,8,8,10,12,16-hexamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-3,8,8,10,12-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9,13,16-hexamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9,16-pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-6,8,8,10,12-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13-cyclohexadecene-2,6-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9-tetramethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13-cyclohexadecene-2,6-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-4,8,8,10,12,16-hexamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-4,8,8,10,12-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-1,5,5,7,9,13-hexamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13-cyclohexadecene-2,6-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-1,5,5,7,9-pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13-cyclohexadecene-2,6-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-13-aza-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-13-aza-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-10-aza-1-oxa-13-cyclohexadecene-2,6-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9-tetramethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-10-aza-1-oxa-13-cyclohexadecene-2,6-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-14-aza-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-14-aza-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-11-aza-1-oxa-13-cyclohexadecene-2,6-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9-tetramethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-11-aza-1-oxa-13-cyclohexadecene-2,6-dione;
- [1S-[1R*,3R*,7R*,10S*,11R*,12R*,16S*]]-N-Phenyl-7,11-dihydroxy-8,8,10,12,16-pentamethyl-5,9-dioxo-4,17-dioxabicyclo[14.1.0]heptadecane-3-carboxamide;
- [1S-[1R*,3R*,7R*,10S*,11R*,12R*,16S*]]-N-Phenyl-7,11-dihydroxy-8,8,10,12-tetramethyl-5,9-dioxo-4,17-dioxabicyclo[14.1.0]heptadecane-3-carboxamide;
- [4S-[4R*,7S*,8R*,9R*,15R*]]-N-Phenyl-4,8-dihydroxy-5,5,7,9,13-pentamethyl-2,6-dioxo-1-oxa-13-cyclohexadecene-16-carboxamide;
- [4S-[4R*,7S*,8R*,9R*,15R*]]-N-Phenyl-4,8-dihydroxy-5,5,7,9-tetramethyl-2,6-dioxo-1-oxa-13-cyclohexadecene-16-carboxamide;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)cyclopropyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)cyclopropyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;
- [4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2-(2-hydroxymethyl-4-thiazolyl)ethenyl]-1-aza-13(Z)-cyclohexadecene-2,6-dione;
- and the pharmaceutically acceptable salts, solvates and hydrates thereof.
37 more elements
A compound having the formula:
- or a pharmaceutically acceptable salt, hydrate, solvate, geometrical isomer, optical isomer or stereoisomer thereof.
A compound of the formula:
- wherein:
- Q is selected from the group consisting of:
- G is selected from the group consisting of alkyl;
- substituted alkyl;
- substituted aryl;
- a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- X is O or H, H;
- Y is selected from the group consisting of O;
- H, OR16;
- OR17, OR17;
- NOR18;
- H, NHOR19;
- H, NR20R21;
- H, H;
- and CHR22;
- wherein OR17, OR17 can be a cyclic ketal;
- Z1 and Z2 are independently CH2;
- B1 and B2 are independently selected from the group consisting of OR24, OCOR25, and O—C(═O)-NR26R27, and when B1 is OH and Y is OH, H, they can form a six-membered ring ketal or acetal;
- R1, R2, R3, R4, R5, R7, R13, R14, R18, R19, R20, R21, R22, R26 and R27 are selected from the group consisting of H, alkyl, substituted alkyl, and aryl, and when R1 and R2 are alkyl can be joined to form a cycloalkyl, and when R3 and R4 are alkyl can be joined to form a cycloalkyl;
- R6 is methyl;
- R9, R10, R16, R17, R24, R25 and R31 are selected from the group consisting of H, alkyl, and substituted alkyl;
- R11, R12, R28, R30, R32, and R33 are selected from the group consisting of H;
- alkyl;
- substituted alkyl;
- aryl;
- substituted aryl;
- cycloalkyl containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C3-C7 carbocyclic ring;
- and a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- R8 is hydrogen or methyl;
- R15, R23 and R29 are selected from the group consisting of H;
- alkyl;
- substituted alkyl;
- aryl;
- substituted aryl;
- cycloalkyl containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C3-C7 carbocyclic ring;
- a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- R32C═O;
- R33SO2;
- hydroxy;
- O-alkyl or O-substituted alkyl;
- or pharmaceutically acceptable salts, hydrates, solvates or geometric, optical or steroisomers thereof.
38 more elements
A compound of the formula:
- wherein:
- Q is selected from the group consisting of:
- G is selected from the group consisting of alkyl;
- substituted alkyl;
- substituted aryl;
- a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- W is O or NR15;
- X is O or H, H;
- Y is selected from the group consisting of O;
- H, OR16;
- OR17, OR17;
- NOR18;
- H, NHOR19;
- H, NR20R21;
- H, H;
- and CHR22;
- wherein OR17, OR17 can be a cyclic ketal;
- Z1 and Z2 are independently CH2;
- B1 and B2 are independently selected from the group consisting of OR24, OCOR25, and O—C(═O)—NR26R27, and when B1 is OH and Y is OH, H, they can form a six-membered ring ketal or acetal;
- R1, R2, R3, R4, R5, R7, R13, R14, R18, R19, R20, R21, R22, R26 and R27 are selected from the group consisting of H, alkyl, substituted alkyl, and aryl, and when R1 and R2 are alkyl can be joined to form a cycloalkyl, and when R3 and R4 are alkyl can be joined to form a cycloalkyl;
- R6 is methyl;
- R9, R10, R16, R17, R24, R25 and R31 are selected from the group consisting of H, alkyl, and substituted alkyl;
- R11, R12, R28, R30, R32, and R33 are selected from the group consisting of H;
- alkyl;
- substituted alkyl;
- aryl;
- substituted aryl;
- cycloalkyl containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C3-C7 carbocyclic ring;
- and a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- R8 is hydrogen or methyl;
- R15, R23 and R29 are selected from the group consisting of H;
- alkyl;
- substituted alkyl;
- aryl;
- substituted aryl;
- cycloalkyl containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C3-C7 carbocyclic ring;
- a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic saturated or unsaturated ring system having between 1 and 3 heteroatoms selected from nitrogen, oxygen, and sulfur;
- R32C═O;
- R33SO2;
- hydroxy;
- O-alkyl or O-substituted alkyl;
- or pharmaceutically acceptable salts, hydrates, solvates or geometric, optical or steroisomers thereof;
- wherein substituted alkyl is an alkyl group substituted with from one to four substituents selected from the group consisting of halo;
- trifluoromethyl;
- trifluoromethoxy;
- hydroxy;
- alkoxy;
- cycloalkoxy;
- heterocyclooxy;
- oxo;
- alkanoyl;
- aryloxy;
- alkanoyloxy;
- amino;
- alkylamino;
- arylamine;
- aralkylamino;
- cycloalkylamino;
- heterocycloamino;
- disubstituted amines wherein the substituents are selected from alkyl, aryl, and aralkyl;
- alkanoylamino;
- optionally substituted with halogen, alkyl, alkoxy, aryl, or araralkyl;
- arylamino optionally substituted with halogen, alkyl, alkoxy, aryl, or araralkyl;
- aralkanoylamino optionally substituted with halogen, alkyl, alkoxy, aryl, or araralkyl;
- thio;
- alkylthio;
- aralkylthio;
- cycloalkylthio;
- heterocyclothio;
- alkylthiono;
- arylthiono;
- aralkylthiono;
- alkylsulfonyl;
- arylsulfonyl;
- aralkylsulfonyl;
- sulfonamido optionally substituted with halogen, alkyl, alkoxy, aryl, or araralkyl;
- nitro;
- cyano;
- carboxy;
- carbamyl optionally substituted with halogen, alkyl, alkoxy, aryl, or araralkyl;
- alkoxycarbonyl;
- aryl;
- substituted aryl;
- guanidino;
- and heterocyclo;
- and
- substituted aryl is an aryl group substituted with from one to four substituents selected from the group consisting of alkyl;
- substituted alkyl;
- halo;
- trifluoromethyl;
- trifluoromethoxy;
- hydroxy;
- alkoxy;
- cycloalkoxy;
- heterocyclooxy;
- alkanoyl;
- alkanoyloxy;
- amino;
- alkylamino;
- aralkylamino;
- cycloalkylamino;
- heterocycloamino;
- dialkylamino;
- alkanoylamino;
- thio;
- alkylthio;
- cycloalkylthio;
- heterocyclothio;
- ureido;
- nitro;
- cyano;
- carboxy;
- carboxyalkyl;
- carbamyl;
- alkoxycarbonyl;
- alkylthiono;
- arylthiono;
- alkylsulfonyl;
- sulfonamido;
- and aryloxy each of which may be optionally substituted with halo, hydroxy, alkyl, alkoxy, substituted aryl, substituted alkyl, or substituted aralkyl;
- with the proviso that compounds wherein
- W and X are both O;
- and
- R1, R2 and R7 are H;
- and
- R3, R4 and R6 are methyl;
- and
- R8 is H or methyl;
- and
- G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl;
- and
- Q is as defined above are excluded.
129 more elements
Dependencies are inferred from the claim text.